Michael Seckler
Vorstandsvorsitzender bei EVOME MEDICAL TECHNOLOGIES INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Michael Seckler
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Direktor/Vorstandsmitglied | 13.06.2023 | - |
| Vorstandsvorsitzender | 13.06.2023 | - | |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Michael Seckler
Ehemalige bekannte Positionen von Michael Seckler
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Geschäftsführer | 01.10.2022 | 01.05.2023 |
| Corporate Officer/Principal | 01.01.2020 | 01.10.2022 | |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Vertrieb & Marketing | 01.03.2003 | 01.12.2019 |
Ausbildung von Michael Seckler
| The Pennsylvania State University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| Kanada | 2 |
Operativ
| Director/Board Member | 2 |
| Sales & Marketing | 1 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Michael Seckler
- Erfahrung
